 |
 |
NIH-NCRR Shared Instrumentation Grant Program
The announcement and guidelines for the FY 2008 NIH National Center for Research Resources Shared Instrumentation Grant ("SIG") Program are available at the following link: http://grants.nih.gov/grants/guide/pa-files/PAR-08-036.html. The appropriate forms must be downloaded from Grants.gov in order to insure that the correct version of the PureEdge forms (version 2A) is being used. Please note that the application deadline
is Monday, March 24, 2008. Applications are limited to instruments
that cost at least $100,000 per instrument or integrated instrument system.
The maximum award under the program is $500,000. NCRR intends to fund
approximately 125 new awards. The earliest anticipated start date is April
1, 2009. Funding decisions will be based on scientific merit, availability
of funds, and relevance of program priorities. The University is eligible to submit more
than one application provided that each is for a different type of equipment.
Types of instruments supported include confocal and electron microscopes,
biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell
sorters and NMR spectrometers, among others. To be eligible, a minimum
of three major users must be Principal Investigators on NIH peer reviewed
research grants at the time of application and award. School of Medicine faculty need to advise
Gayle Mowbray Walters (email: gmwalters@jhmi.edu;
7-0702) in Research Administration of your interest in applying for this
program and the type of equipment no later than Friday, February 1, 2008,
so that we can determine if more than one group wants to apply for the
same type of equipment. She can also provide a list of equipment previously
awarded under the SIG program. Installation, alterations, renovations,
and operating costs must be supported by departmental funds existing at
the time of proposal. Faculty from other divisions of the University should
contact their designated ORA representative. If more than one division
of the University wishes to apply for the same kind of instrumentation,
a letter from the Vice Provost for Research will be drafted by the applicant
PIs to document lack of overlap/duplication. Large-scale sharing of needed instruments
by sizable groups of PHS peer-review funded researchers is important for
the application to succeed. Duplication of instruments previously awarded
under this program will weaken the review score unless a current, unmet
need is well documented. Thank you for considering this important grant
program.
NIH is calling for applications for 2008 NIH Director's Pioneer Awards and New Innovator Awards. Both programs are part of the NIH Roadmap for Medical Research and support exceptionally creative scientists who take highly innovative approaches to major challenges in biomedical or behavioral research. Pioneer Awards provide $2.5 million in direct costs over 5 years and are open to scientists at any career stage. New Innovator Awards provide $1.5 million in direct costs over the same period and are for new investigators who have not received an NIH regular research (R01) or similar grant. NIH expects to make 5 to 10 Pioneer Awards and up to 24 New Innovator Awards in September 2008. Women and members of groups that are underrepresented in NIH research areas are encouraged to apply. The Pioneer Award application period is from December 16, 2007 to January 16, 2008. See http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-013.html for application instructions and http://nihroadmap.nih.gov/pioneer for more information. Send questions to pioneer@nih.gov. Submit New Innovator Award applications between March 3 and 31, 2008. Application instructions are at http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-014.html and additional information is at http://grants.nih.gov/grants/new_investigators/innovator_award. Send questions to newinnovator@nih.gov.
Funding is available to support multidisciplinary research in prostate cancer through the Patrick C. Walsh Prostate Cancer Research Fund. Awards of a maximum of $75,000 for up to 2 years are available to fund career development and developmental research programs (pilot projects). New Ideas Encouraged! Deadline: Monday, January 7, 2008 For more information visit: http://prostatecancerprogram.onc.jhmi.edu/
This FOA invites applications for projects that will examine, through molecular approaches, the relationship between changes in the human microbiome and human health and disease. This FOA will use the UH2/UH3 cooperative agreement mechanisms to support the demonstration project awards. The program will be funded in two phases, as allowed by this mechanism. The initial one-year pilot phase (UH2) will allow investigators to procure samples and generate data that will be used to support the scale-up phase (UH3), which will be awarded after administrative review to those projects that have the most promise to demonstrate whether or not the human microbiome plays an important role in human health and disease. The total amount of funds available for these awards is approximately $4million total costs for the UH2 in FY 09 and $24.3 million for the UH3 in FY 10-12. Up to 10 UH2 and 5 UH3 awards are anticipated from this solicitation. Letters of intent must be submitted by April 22, 2008 and the application deadline is May 22, 2008. To view the complete announcement, click here: http://www.grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-012.html.
The goal of this initiative is to create a center (or centers) to 1) evaluate new monoclonal antibodies (mABs) to neurodevelopmental antigens using multiple model systems and 2) provide detailed information for use of these reagents to the research community. Some of the most powerful tools in understanding nervous system development are antibodies that monitor the expression of key developmental proteins. Accordingly, one of the most compelling needs within the community is greater access to well-validated mABs. As an initial step to address this need, the NIH Blueprint for Neuroscience Research (subsequently referred to as the Blueprint) is currently funding the targeted creation and distribution of a large number of high quality monoclonal antibodies via the Blueprint Resource Antibodies Initiative for Neurodevelopment (BRAINdev) in partnership with the UC Davis/NINDS/NIMH NeuroMab Facility (www.neuromab.org). To fulfill the evaluation portion of this plan, this Funding Opportunity Announcement (FOA) solicits applications directed toward the creation of a center (or centers) to perform further examination of mABs immunoreactivity in the developing central and peripheral nervous systems of multiple model systems. This announcement specifically requests the creation of antibody evaluation centers which will, in total, determine the ability of antibodies to recognize their corresponding antigen during development in the following organisms: fruit fly (D. melanogaster), nematode (C. elegans), zebrafish (D. rerio), mouse (M. musculus), chick (G. gallus), frog (X. laevis and X. tropicalis), rat (R. norvegicus), rhesus monkey (M. mulatta) and human (H. sapiens). Individual centers will establish experimental conditions for antibody use during development, including immunoblotting, and immunohistochemistry in at least five species, as well as provide these data to the neurodevelopment community. This FOA uses the Resource-Related Research Projects-Cooperative Agreement (U24) award mechanism. The Blueprint is a framework to enhance cooperative activities among the NIH Office of the Director and 15 NIH Institutes and Centers (ICs) that support research on the central and peripheral nervous systems. In fiscal year 2008, the Blueprint is emphasizing
neural development. The participating Blueprint organizations intend to
commit $1,200,000 over a two-year period to fund 1 to 3 applications in
response to this FOA. Letters of intent must be received by January
15, 2008 and the application deadline is February 15, 2008. To view
this complete announcement, click here: http://www.grants.nih.gov/grants/guide/rfa-files/RFA-NS-08-
This funding opportunity encourages new research applications proposing research on hPSCs from non-embryonic sources. This FOA addresses the Executive Order issued by
President George W. Bush on June 20, 2007, requiring that the Secretary
of Health and Human Services conduct and support research on the isolation,
derivation, production, and testing of stem cells that are capable of
producing all or almost all of the cell types of the developing body and
may result in improved understanding of or treatments for diseases and
other adverse This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-044, that encourages applications under the NIH Exploratory/Developmental (R21) grant award mechanism. The earliest an R01 application may be submitted
is January 5th and the earliest an R21 application may be submitted is
January 16th. Standard dates apply for application submission. The R01
announcement can be found here: http://www.grants.nih.gov/
This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1- 100 nanometers, where novel properties and functions occur because of the size. This Funding Opportunity Announcement (FOA)
will utilize the R01 grant mechanism and runs in parallel with a FOA of
identical scientific scope PA-08-053, that solicits applications under
the R21 mechanism. The earliest an R01 application may be submitted is
February 5th and the earliest an R21 application may be submitted is January
16th. Standard dates apply for application submission. The R01 announcement
can be found here: http://www.grants.nih.gov/grants/guide/pa-files/PA-
This announcement details an administrative supplement
program of $600,000 in Fiscal Year 2008 to provide funds to NINDS, NIMH,
NIDCD or NIAAA-funded research projects for collaboration with the UC
Davis NeuroMab Facility (www.neuromab.org).
The purpose of this program is to facilitate production of new monoclonal
antibodies (NeuroMabs) to targets with high relevance to nervous system
studies. The NeuroMab Facility was established to provide inexpensive,
carefully verified monoclonal antibodies to proteins of the mammalian
nervous system. For investigator-initiated antibody requests, the facility
enters into a collaborative partnership in which the requesting investigator
can provide expertise and reagents necessary for the project. The current To be eligible, projects must be actively funded
in fiscal year 2008. Review criteria are provided in the complete announcement
(click here: http://www.grants.nih.gov/ Investigators are strongly encouraged to contact
the NeuroMab Facility (neuromab@
|
 |
|
||||||
|
|
|
|
|
JHM Appointments | Employment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM |
|
|
